VolitionRx ends Volition Veterinary CEO role in cost-realignment move

VolitionRx Limited reported a leadership change at its majority-owned subsidiary, Volition Veterinary Diagnostics Development, LLC.

Accepted by SEC EDGAR 12/11/2025 - 05:00 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

VolitionRx Limited reported a leadership change at its majority-owned subsidiary, Volition Veterinary Diagnostics Development, LLC. On December 5, 2025, Volition Veterinary gave notice to terminate the employment agreement of its Chief Executive Officer, Dr. Salvatore Thomas Butera, effective January 31, 2026. The company states this decision was made for operational reasons and not due to any disagreement or dispute about operations, policies, or practices. As part of ongoing cost-realignment efforts, Volition Veterinary will eliminate the Chief Executive Officer position and redistribute Dr. Butera’s duties within the organization. After his employment ends, Dr. Butera is expected to continue with Volition Veterinary on a part-time consulting basis, providing advisory services under mutually agreed terms.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership change did VolitionRx (VNRX) announce at Volition Veterinary?

VolitionRx announced that Volition Veterinary Diagnostics Development, LLC will terminate the employment agreement of its Chief Executive Officer, Dr. Salvatore Thomas Butera, effective January 31, 2026, and eliminate the Chief Executive Officer role.

Why is Dr. Salvatore Thomas Butera leaving his CEO role at Volition Veterinary under VolitionRx (VNRX)?

The company states that ending Dr. Butera’s employment was an operational decision tied to cost-realignment efforts and was not the result of any disagreement or dispute over operations, policies, or practices.

Will Volition Veterinary under VolitionRx (VNRX) replace the Chief Executive Officer position?

No. Effective January 31, 2026, Volition Veterinary will eliminate the Chief Executive Officer position and redistribute the responsibilities that had been handled by Dr. Butera.

Will Dr. Butera continue to work with VolitionRx’s subsidiary after his CEO role ends?

Yes. Following the termination date, it is intended that Dr. Butera will remain with Volition Veterinary on a part-time consulting basis, providing advisory services on mutually agreed terms.

When does the leadership change at Volition Veterinary, a subsidiary of VolitionRx (VNRX), take effect?

The notice of termination was given on December 5, 2025, and the change takes effect on January 31, 2026, when Dr. Butera’s employment as Chief Executive Officer ends.

How does this change relate to VolitionRx’s (VNRX) broader business strategy?

The elimination of the Chief Executive Officer role at Volition Veterinary is described as part of VolitionRx’s ongoing cost-realignment efforts, with Dr. Butera’s duties to be redistributed within the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0000093314false00000933142025-12-052025-12-05iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 5, 2025

VolitionRx Limited

(Exact name of registrant as specified in its charter)

Delaware		001-36833		91-1949078
(State or other jurisdiction		(Commission		(IRS Employer
of Incorporation)		File Number)		Identification Number)

1489 West Warm Springs Road, Suite 110

Henderson, Nevada 89014

(Address of principal executive offices and zip code)

+1 (512) 774-8930

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed from last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on which Registered
Common Stock, par value $0.001 per share		VNRX		NYSE American, LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 5, 2025, Volition Veterinary Diagnostics Development, LLC (“Volition Veterinary”), a majority-owned subsidiary of VolitionRx Limited (the “Company”), provided notice of termination of its employment agreement with Dr. Salvatore Thomas Butera, the Chief Executive Officer of Volition Veterinary, effective as of January 31, 2026 (the “Termination Date”).  The decision to end Dr. Butera’s employment was made for operational reasons and not as a result of any disagreement or dispute with the Company on any matter relating to the Company’s operations, policies or practices.

Effective January 31, 2026, Volition Veterinary will eliminate the Chief Executive Officer position as part of the Company’s ongoing cost-realignment efforts. Dr. Butera’s duties will be redistributed within the Company.

Following the Termination Date, it is intended that Dr. Butera will remain with Volition Veterinary on a part-time consulting basis, providing advisory services, subject to mutually agreed upon terms.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VOLITIONRX LIMITED
Date: December 11, 2025	By:	/s/ Cameron Reynolds
		Cameron Reynolds
		Chief Executive Officer & President

3